NASDAQ: CSTLCastle Biosciences Inc Stock
$20.12-0.89 (-4.24%)
Updated Jun 8, 2026
CSTL Price
$20.12
Fair Value Price
N/A
Market Cap
$610.24M
52 Week Low
$14.59
52 Week High
$44.28
P/E
-47.9x
P/B
1.32x
P/S
2.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$339.92M
Earnings
-$12.83M
Gross Margin
77.9%
Operating Margin
-5.13%
Profit Margin
-3.8%
Debt to Equity
0.19
Operating Cash Flow
$48M
Beta
1.47
Next Earnings
Aug 3, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CSTL Overview
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CSTL's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
CSTL
Ranked#41 of 45
Ranked#41 of 45
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $21.95 | A | |
| $132.69 | B | |
| $15.86 | B |
Be the first to know about important CSTL news, forecast changes, insider trades & much more!
CSTL News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CSTL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CSTL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CSTL is good value based on its book value relative to its share price (1.32x), compared to the US Diagnostics & Research industry average (3.53x)
P/B vs Industry Valuation
CSTL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CSTL due diligence checks available for Premium users.
Valuation
CSTL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-47.9x
Industry
16.92x
Market
14.72x
CSTL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.32x
Industry
3.53x
CSTL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CSTL's financial health
Profit margin
Revenue
$83.7M
Net Income
-$14.5M
Profit Margin
-17.4%
CSTL's Earnings (EBIT) of -$17.45M... subscribe to Premium to read more.
Interest Coverage Financials
CSTL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$547.8M
Liabilities
$86.4M
Debt to equity
0.19
CSTL's short-term assets ($328.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CSTL's short-term assets ($328.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CSTL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CSTL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.1M
Investing
-$25.8M
Financing
-$5.0M
CSTL's operating cash flow ($48.25M)... subscribe to Premium to read more.
Debt Coverage Financials
CSTL vs Diagnostic & Research Stocks
Castle Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.